

CITATION REPORT

List of articles citing

Sildenafil in Heart failure (SilHF). An investigator-initiated multinational randomized controlled clinical trial: rationale and design

DOI: 10.1093/eurjhf/hfs152

European Journal of Heart Failure, 2013, 15, 119-22.

Source: <https://exaly.com/paper-pdf/56588834/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
41	Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizons. <i>Arab Journal of Urology Arab Association of Urology</i> , 2013 , 11, 222-9	1.7	24
40	Pulmonary hypertension due to left heart diseases. <i>Journal of the American College of Cardiology</i> , 2013 , 62, D100-8	15.1	437
39	Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics. <i>Future Cardiology</i> , 2013 , 9, 335-49	1.3	26
38	Impact of bosentan on exercise capacity in adults after the Fontan procedure: a randomized controlled trial. <i>European Journal of Heart Failure</i> , 2013 , 15, 690-8	12.3	96
37	Pulmonary hypertension caused by pulmonary venous hypertension. <i>Pulmonary Circulation</i> , 2014 , 4, 581-95	2.5	13
36	Additional use of a phosphodiesterase 5 inhibitor in patients with pulmonary hypertension secondary to chronic systolic heart failure: a meta-analysis. <i>European Journal of Heart Failure</i> , 2014 , 16, 444-53	12.3	19
35	Sildenafil treatment in established right ventricular dysfunction improves diastolic function and attenuates interstitial fibrosis independent from afterload. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2014 , 307, H361-9	5.2	24
34	Should there be sex-specific criteria for the diagnosis and treatment of heart failure?. <i>Journal of Cardiovascular Translational Research</i> , 2014 , 7, 139-55	3.3	29
33	Pathophysiology and potential treatments of pulmonary hypertension due to systolic left heart failure. <i>Acta Physiologica</i> , 2014 , 211, 314-33	5.6	12
32	Novel drug targets in clinical development for heart failure. <i>European Journal of Clinical Pharmacology</i> , 2014 , 70, 765-74	2.8	17
31	Noninvasive estimation of pulmonary vasculature -- why it is important. <i>Circulation Journal</i> , 2015 , 79, 2324-5	2.9	2
30	Current Treatment Strategies in Pulmonary Hypertension Associated with Left Heart Disease. <i>Current Transplantation Reports</i> , 2015 , 2, 345-354	1.5	1
29	Straining the RV to predict the future. <i>JACC: Cardiovascular Imaging</i> , 2015 , 8, 170-1	8.4	6
28	Comparative effectiveness of sildenafil for pulmonary hypertension due to left heart disease with HFrEF. <i>Hypertension Research</i> , 2015 , 38, 829-39	4.7	11
27	Increased pulmonary vascular resistance, right ventricular dysfunction, and reversible pulmonary vasoconstriction in type 2 pulmonary hypertension: who has it and are we missing a potential therapeutic target in patients with heart failure?. <i>European Journal of Heart Failure</i> , 2015 , 17, 237-8	12.3	2
26	What constitutes optimal neurohumoral antagonism in chronic heart failure?. <i>Heart</i> , 2016 , 102, 1922-1932	3.1	2
25	Treatment of advanced group 2 PH. <i>Progress in Cardiovascular Diseases</i> , 2016 , 59, 78-86	8.5	

24	Sildenafil in heart failure with reactive pulmonary hypertension (Sildenafil HF) clinical trial (rationale and design). <i>Pulmonary Circulation</i> , 2016 , 6, 161-7	2.7	6
23	Combined post- and pre-capillary pulmonary hypertension in heart failure with preserved ejection fraction. <i>Heart Failure Reviews</i> , 2016 , 21, 285-97	5	19
22	Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work?. <i>Journal of Endocrinological Investigation</i> , 2016 , 39, 131-42	5.2	18
21	New pharmacological approaches in heart failure therapy: developments and possibilities. <i>Future Cardiology</i> , 2017 , 13, 173-188	1.3	
20	Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. <i>European Heart Journal</i> , 2018 , 39, 1255-1264	9.5	105
19	Models and Molecular Mechanisms of World Health Organization Group 2 to 4 Pulmonary Hypertension. <i>Hypertension</i> , 2018 , 71, 34-55	8.5	11
18	Classification and pathophysiology of pulmonary hypertension. <i>Continuing Cardiology Education</i> , 2018 , 4, 2-12		16
17	Pulmonary Hypertension Due to Left Heart Disease: an Update. <i>Current Cardiology Reports</i> , 2019 , 21, 62	4.2	8
16	Challenges in pulmonary hypertension associated with left heart disease. <i>Expert Review of Cardiovascular Therapy</i> , 2019 , 17, 461-472	2.5	1
15	Phosphodiesterase 5 inhibitors for pulmonary hypertension. <i>The Cochrane Library</i> , 2019 , 1, CD012621	5.2	32
14	New perspectives and future directions in the treatment of heart failure. <i>Heart Failure Reviews</i> , 2020 , 25, 147-159	5	17
13	Cardiac magnetic resonance imaging as a prognostic biomarker in treatment-naïve pulmonary hypertension. <i>European Journal of Radiology</i> , 2020 , 123, 108784	4.7	3
12	Effectiveness of Sildenafil in Pulmonary Hypertension Secondary to Valvular Heart Disease: A Systematic Review and Meta-Analysis. <i>Archives of Pharmacy Practice</i> , 2021 , 12, 55-65	0	0
11	Right Ventricular Structure and Function During Exercise. 2014 , 83-98		2
10	Pre-Operative Sildenafil for Patients With Pulmonary Hypertension Undergoing Mitral Valve Surgery: A Systematic Review and Meta-Analysis. <i>Cardiology Research</i> , 2019 , 10, 369-377	1.8	6
9	Overview of WHO Group 2 Pulmonary Hypertension Due to Left Heart Disease. <i>Advances in Pulmonary Hypertension</i> , 2015 , 14, 70-78	0.5	4
8	Pulmonary Hypertension in Patients Without Pulmonary Arterial Hypertension. 2016 , 29-61		
7	Pulmonary Hypertension in General Cardiology Practice. <i>Arquivos Brasileiros De Cardiologia</i> , 2019 , 113, 419-428	1.2	2

6	Phosphodiesterase-5 inhibitors. <i>Handbook of Experimental Pharmacology</i> , 2013 , 218, 229-55	3.2	2
5	Future perspective in diabetic patients with pre- and post-capillary pulmonary hypertension.. <i>Heart Failure Reviews</i> , 2022 , 1	5	2
4	A text messaging intervention and quality of life in adolescents with solid organ transplants.. <i>Pediatric Transplantation</i> , 2022 , e14219	1.8	0
3	Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (The SilHF study): A randomised placebo-controlled multicentre trial. <i>European Journal of Heart Failure</i> ,	12.3	1
2	Pulmonary hypertension associated with left-sided heart disease. 2017 , 147, w14395		0
1	Pathogenesis of pulmonary hypertension caused by left heart disease. 10,		0